Condition
Ulcerative colitis news across medications, symptoms, monitoring, procedures, research, access, and daily life.
Page 5 of 40 · 1913 articles
IBD affects more than the digestive tract and long-term care now emphasizes controlling inflammation and monitoring (including endoscopic healing) to lower complication risk and improve quality of life.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from British medical...
Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis and Symptoms and flares. The original article is from British medical journal (Clinical research ed.).
Wearable-derived digital biomarkers could enable earlier, less burdensome detection of IBD flares and better remote monitoring if they reliably predict mucosal inflammation.
A phase 2 trial tested whether repurposing fenofibrate (a lipid-lowering PPAR-α agonist) added to mesalamine can reduce disease activity and improve quality of life in adults with mild-to-moderate ulcerative colitis.
This trial tests whether adding the oral antibiotic nifuroxazide to standard mesalamine improves quality of life for people with mild-to-moderate ulcerative colitis. Results, if published, could suggest a new adjunctive...
Dietary change is a low-risk intervention many patients try; this trial specifically tested whether a gluten-free diet affects liver disease markers, intestinal inflammation, and the gut microbiome in PSC and UC...
The study suggests a decade-long preclinical phase of IBD detectable by blood metabolites, which could open opportunities for earlier identification of people at risk for Crohn’s disease and for studying early disease...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Patient Related Outcome...
People with ulcerative colitis may be interested because the study explores a way to boost curcumin’s activity and suggests gut microbiota changes could underlie protection against colitis.
Holiday-related stress, disrupted routines, and dietary changes can increase the chance of IBD symptom flares. Simple, practical steps can reduce stress and help maintain symptom control during the season.
If true, the finding explains why symptoms can return after remission: the gut lining may remain biologically vulnerable even when inflammation seems controlled. That could point to new approaches aimed at 'molecular...
Cure8 could only read part of this source from Endoscopy, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring.
Patients and clinicians may see continued availability and promotion of Skyrizi and Rinvoq across IBD indications, which can affect prescribing options and market competition. Sales growth and approvals also influence...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Mesalamine. The original article is from Drugs - Real World Outcomes.
Early human data suggest PALI-2108 reaches intestinal tissue and produced short-term clinical, endoscopic, and biomarker changes in very small Phase 1 cohorts, supporting larger Phase 2 trials that could determine if...
People with ulcerative colitis may be interested because the review identifies flavonoids in propolis as compounds that reduce inflammation and strengthen the gut barrier in animal models, and it highlights strategies to...
A breath-based VOC test could offer a noninvasive, point-of-care way to help detect or screen for colon diseases including IBD. This study shows preliminary promise—especially for ulcerative colitis—but is early-stage...
A sizable minority of people newly diagnosed with IBD—about 1 in 5 with Crohn’s and 1 in 10 with ulcerative colitis—received no IBD-specific drugs within the first year. Understanding who is untreated and why could...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from The Egyptian Journal...
Early Phase 1 findings suggest a gut-targeted PDE4 prodrug may engage its target in diseased tissue and produce early improvements in symptoms, endoscopy, and tissue inflammation — findings that, if confirmed in Phase 2,...
Improving mesalazine delivery could increase drug reaching the colon and potentially improve treatment for ulcerative colitis. A formulation that both enhances dissolution/permeability and offers mechanistic synergy...
The review links microbiome, metabolites, barrier function, and immune responses across anorectal disorders and ulcerative colitis — areas that directly affect symptoms, healing, and response to therapy.
People with IBD often ask about dietary supplements. This systematic review suggests some randomized-trial evidence that polyphenol supplements—especially curcumin—may help induce clinical improvement in ulcerative...
Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease. The original article is from msn.com.
Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for...
A colon-targeted IFX formulation could deliver the drug directly to inflamed tissue, potentially improving effectiveness and lowering systemic side effects or dosing complexity for people with ulcerative colitis.
This study describes how often people newly diagnosed with IBD go on biologic or JAK inhibitor therapy and what happened to them over five years — including hospital visits and surgery — which helps set expectations for...
The study suggests that about one-quarter of IBD patients treated with advanced therapies develop difficult-to-treat disease, and identifies timing of therapy, age, and specific therapy choice as predictors.
People with ulcerative colitis can rarely develop inflammatory complications outside the gut, including central nervous system vasculitis that can look like a brain tumor. Recognizing this can change diagnosis and...
New long‑term and real‑world data for risankizumab and upadacitinib were presented at ACG 2026, which may influence treatment considerations for people with difficult‑to‑treat Crohn's disease and ulcerative colitis.
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Infliximab.
AMNs are rare but can be malignant and may mimic UC flares or appendicitis, which can delay diagnosis. For people with long-standing UC, awareness may prompt appropriate imaging and surgical referral.
IBD cases are increasing in Sub-Saharan Africa but care and research remain limited and driven by high-income country priorities. Region-specific research and policy changes could improve diagnosis, treatment access, and...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis, Inflammatory bowel disease, and Complications. The original article is from Asian Journal of...
This study raises pharmacovigilance signals and mechanistic hypotheses about liraglutide in people with ulcerative colitis — important because GLP-1 drugs are widely used and are being studied for inflammatory effects....
Modeled cost savings and fewer hospital visits could affect access to infliximab for people with Crohn’s disease and other autoimmune conditions in Jordan, potentially increasing the number of patients who can be treated...
This study links higher mucosal PD-L1 expression to active IBD and routine disease activity measures, suggesting the PD-1/PD-L1 immune checkpoint may be involved in intestinal inflammation and could be a biomarker or...
A reliable blood biomarker that predicts relapse while a person with UC is in remission could help tailor monitoring intensity and treatment decisions.
The study identifies a bile acid, TUDCA, that reduced colitis severity and improved gut-barrier and antioxidant pathways in mice, pointing to a potential new therapeutic approach for intestinal inflammation. This is...
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Mesalamine. The original article is from BMJ case reports.
Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.
Recognition of a local IBD leader signals available specialized multidisciplinary care and ongoing clinical trials activity at UCI Health — relevant for patients seeking advanced treatment or trial participation. It also...
Automated, objective scoring of colonoscopy images could reduce variability in Mayo Endoscopic Score assignment and support treatment decisions and monitoring for people with ulcerative colitis.
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Disinformation Security...
These Day 1 scores aim to identify patients unlikely to respond to IV steroids so treatment can be escalated earlier; that could shorten delays to rescue therapy and potentially improve outcomes for people admitted with...
